Intensity Therapeutics Inc
NASDAQ:INTS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Huber+Suhner AG
SIX:HUBN
|
CH |
|
Deceuninck NV
LSE:0MEL
|
BE |
|
Challenger Energy Group PLC
LSE:CEG
|
IM |
|
O
|
Oriental Hotels Ltd
NSE:ORIENTHOT
|
IN |
|
Comany Inc
TSE:7945
|
JP |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (0.1), the stock would be worth $-5.23 (196% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | $5.46 |
0%
|
| 3-Year Average | 0.1 | $-5.23 |
-196%
|
| 5-Year Average | 0.1 | $-5.23 |
-196%
|
| Industry Average | 13.3 | $-466.43 |
-8 643%
|
| Country Average | 14.4 | $-503.47 |
-9 321%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
I
|
Intensity Therapeutics Inc
NASDAQ:INTS
|
13.8m USD | -0.2 | -1.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365B USD | 14.5 | 87.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD | 14.2 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 12.7 | 20.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 21.2 | 28.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 13 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 40.9 | 37.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 10.9 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Intensity Therapeutics Inc
Glance View
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Westport, Connecticut and currently employs 3 full-time employees. The company went IPO on 2023-06-30. The firm is engaged in developing an approach to treat solid tumor cancers. The company leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The firm's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. The company also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725).
